Format

Send to

Choose Destination
Trends Mol Med. 2007 Nov;13(11):470-81. Epub 2007 Nov 5.

Right on target: eradicating leukemic stem cells.

Author information

1
Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.

Abstract

Less than a third of adults with acute myeloid leukemia (AML) are cured by current treatments, emphasizing the need for new approaches to therapy. The discovery over a decade ago that myeloid leukemias originate from rare stem-like cells that can transfer the disease to immunodeficient mice suggested that these 'leukemia stem cells' (LSCs) are responsible for relapse of leukemia following conventional or targeted cancer therapy and that eradication of LSCs might be necessary to cure the disease permanently. Several recent studies have provided insight into the signaling pathways underlying the LSC phenotype and have also described approaches to eliminate LSCs with antibodies. Here, we review recent advances in LSC research and discuss novel therapeutic strategies to specifically target LSCs.

PMID:
17981087
PMCID:
PMC4344828
DOI:
10.1016/j.molmed.2007.09.003
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center